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Abstract 
The 7-valent pneumococcal conjugate vaccine (PCV7) has been shown to be highly cost-
effective. The 13-valent pneumococcal conjugate vaccine (PCV13) offers seroprotection 
against six additional serotypes. A decision-analytic model was constructed to estimate 
direct medical costs and clinical effectiveness of PCV13 vaccination on invasive 
pneumococcal disease (IPD), pneumonia, and otitis media relative to PCV7 vaccination. 
The option with an one-dose catch-up vaccination in children of 15-59 months was also 
considered. Assuming 83% vaccination coverage and considering indirect effects, 1’808 
IPD, 5'558 pneumonia and 74’136 otitis media cases could be eliminated from the entire 
population during a 10-year modelling period. The PCV13 vaccination programme would 
lead to additional costs (+€26.2 Mio), but saved medical costs of -€77.1 Mio due to cases 
averted and deaths avoided, overcompensate these costs (total cost savings -€50.9 Mio). 
The national immunization programmes with PCV13 can be assumed cost saving when 
compared with the current vaccine PCV7 in Switzerland.  
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I. Background 
Streptococcus pneumoniae (pneumococcus) is a bacterial pathogen causing about 1-2 
million death among children worldwide
1-3
. Generally, the pathogen colonises in the 
upper respiratory tract causing pneumonia, bacteremia, meningitis and otitis media which 
are associated with considerable numbers of cases of morbidity and mortality
4
. Invasive 
pneumococcal disease (IPD) like bacteremia, bacteremic pneumonia or meningitis is 
most prevalent among children, the immunocompromised and the elderly
5
. The 
transmission of pneumococcus requires direct contact with contaminated respiratory 
secretions between individuals
6
. However, the underlining treatment of the infections is 
often complicated due to resistance of the pathogen to several classes of antibiotics
7
.  
The 7-valent protein conjugated pneumococcal vaccine (PCV7, Prevenar®, Pfizer) was 
shown to be highly efficacious in preventing invasive pneumococcal infections, 
pneumonia and otitis media in infants as well as in young children
8-10
. The 13-valent 
vaccine (PCV13, Prevenar 13®, Pfizer) includes six additional serotypes, including 
serotype 19A which is associated with increased disease rates and hospital admission 
after the introduction of PCV7
11
. The American Academy of Pediatrics Committee on 
Infectious Diseases postulated that PCV7 should be replaced by PCV13, and used in 
health and children at-risk
12
  
Given that pneumococcal vaccines can decline nasopharyngeal carriage of vaccine strains 
in vaccinated children, the rate of pneumococcal disease in non-immunized individuals 
can be reduced, designated as indirect or herd effect
13
. Cost-effectiveness studies take 
generally both the direct and indirect effect of immunisation into account to provide a 
more comprehensive evaluation of the vaccine
14
.  
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It was shown that pneumococcal conjugate immunisation programmes can reduce 
mortality and long term neurologic impairment at a reasonable cost-effectiveness ratio for 
Swiss infants
15, 16
. The pneumococcal vaccination schedule is a 2+1 schedule in 
Switzerland
17
. In 2010, PCV13 has been approved by the Swiss Agency for Therapeutic 
Products (Swissmedic)
18
.  
The objective of the present study is to assess the potential health benefits and costs 
associated with pneumococcal vaccination strategies for the entire population. A 
decision-analytic model was used to simulate a Swiss birth cohort during a ten-year 
horizon.  
II. Methods 
2.1. Overview of the model 
The aim of this model was to assess the clinical and economic consequences in 
Switzerland, in particular, of the 13-valent conjugated pneumococcal vaccine (PCV13), 
with or without serotype catch-up vaccination, versus the 7-valent vaccine (PCV7,). A 
decision analysis model was applied to an annual birth cohort of 77'019 children
19-
21
(Figure 1).  
The model considered various disease states including no disease, IPD (i.e. bacteremia or 
meningitis), inpatient and outpatient pneumonia and otitis media (complex and simple). 
For each disease state, the percentage of disease covered by the vaccine's serotype (for 
serotype covered disease), the vaccine coverage rate and the direct and indirect effect 
(herd effect) of the vaccine were applied to the entire population within each age-group. 
Direct and indirect effect of the vaccine was applied to vaccinated and unvaccinated 
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individuals, respectively. Within each health states corresponding costs (direct medical 
costs per episode and vaccine acquisition and administration, where applicable) and 
utilities were assessed in each vaccination strategy.  
Effectiveness was determined as quality-adjusted life-years (QALYs) and life year gained 
(LYG). Cumulative direct costs associated with each vaccination programme were 
estimated. Incremental cost-effectiveness ratios (ICERs) were planned to be measured if 
applicable.  
Demographic information on the Swiss patient population, data on disease incidence and 
fatality rates, direct costs, vaccine properties and utility inputs were determined to 
estimate the cost-effectiveness of the scenarios described above. Costs and effects were 
discounted at 3%. Costs are shown in Euros (1 Swiss Francs (CHF) = 0.82 Euro (EUR), 
February 2012). The model time horizon was ten years.  
2.2. Patient population studied 
The model was constructed with a hypothetical cohort of the general population in 
Switzerland. Total population, percentage of the population in the newborn cohort (below 
the age of 1 year) and the proportion of the vaccinated population were assessed from the 
Swiss perspective
21
. In Switzerland, the pneumococcal vaccination coverage rate in 
children below 2 years of age is currently 83%. The model assumed a constant coverage 
rate throughout the modelling period.  
The model distinguished between different age groups (0-2, 2-4, 5-17, 18-34, 35-49, 50-
64, 65+ years) and the incidence of disease in those age groups for Switzerland (Table 1). 
Due to different event probabilities, age-stratification was crucial to our analysis. 
Children below the age of 5 were eligible for vaccination. The adult population in our 
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model was assumed to be unvaccinated. Life expectancy in Switzerland is 79.7 and 84.4 
years for males and females, respectively
22
.  
2.3. Strategies compared 
Base-case 
In the base-case, the model considered two strategies: 7-valent vaccine (PCV7) versus 
13-valent conjugated pneumococcal vaccine (PCV13). In Switzerland, pneumococcal 
vaccination schedule is a 2+1 schedule (2 primary vaccination at age of 2 month and 4 
month and one booster dose at age of 12 month)
17
. Due to low clinical relevance, the 
strategy with no vaccination was not taken into account.  
Catch-up 
An additional analysis considered PCV13 versus PCV13 with catch-up vaccination. The 
PCV13 serotype catch-up strategy intended to administer one additional dose of PCV13 
to children who completed their PCV7 series. This option assumed that children aged 15-
59 months will accelerate the direct and indirect effect due to one dose of PCV13 by 1 
year
23
. The vaccination rate of the catch-up strategy was assumed at 15%. 
2.4. Disease stages 
The model included six different health states: no disease, IPD (i.e. IPD that are 
pneumococcal meningitis or pneumococcal bacteremia), inpatient pneumonia, outpatient 
pneumonia, simple and  complex all-cause  otitis media (Figure 1). IPD cases are 
clinically defined by isolating Streptococcus pneumoniae from a normally sterile body 
site
24
. In our case, IPD was confirmed by clinical syndromes and classified as pneumonia, 
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bacteraemia, meningitis or arthritis
25
. The latter symptom was not considered in our 
model.  
Patients contracting meningitis were prone to develop sequelae such as neurological 
impairment or hearing loss (mutually exclusive). These conditions were assumed to 
increase costs of health care service and reduce a patient’s lifetime utility by 
decrementing the baseline utility and persisting for the remainder life. Patients 
contracting bacteremia, meningitis, and pneumonia were assumed to have an increased 
risk of death due to illness specific conditions. The remainder were supposed to recover 
from the disease. All-cause mortality was estimated from the age distribution of the 
patient population and the conditional expected remaining life years by each age-group.  
2.5. Clinical data source  
Incidence of disease 
Streptococcus pneumoniae can cause different diseases. The Incidence per age group for 
IPD (meningitis, bacteremia, pneumonia), hospitalised CAP and all-cause otitis media ( 
derived from the Federal Office of Public Health Switzerland (FOPH) and the Institute 
for Infectious Diseases (IFIK) Berne, Switzerland
26. The numbers of cases (per 100’000 
individuals) of each disease for the year 2007 or 2008 are presented in Table 1, 
respectively. Fatality rates classified by age group and disease were presented in Table 2. 
Complication rates were assessed from published literature
27
. Neurologic impairment or 
hearing loss due to meningitis were assumed to occur in 7% or 13%, respectively
27
.  
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Serotype coverage 
The serotypes covered by PCV7 (4; 6B; 9V; 14; 18C; 19F; 23F ) and PCV13 (1; 3; 4; 5; 
6A; 6B; 7F; 9V; 14; 18C; 19A; 19F; 23F), respectively, were considered by disease and 
age class within the model. IPD was assumed to be serotype covered while pneumonia 
and otitis media was all-cause. Given that pneumonia and otitis media were from an all-
cause perspective, the serotype coverage was implicitly taken into account for calculating 
vaccine effectiveness.  
Serotype coverage was assessed from the database of the FOPH and the IFIK
26
 (Table 3). 
The inputs of the PCV7 serotype coverage reflects the coverage of the time of its 
introduction
25
 (reimbursement in Switzerland since August 2006). Serotype coverage of 
PCV13 was considered from the year 2008 to reveal the coverage in the selected era of 
the disease incidence.  
Vaccine direct effect 
Direct effectiveness is represented by the reduction in disease among vaccinated 
individuals. PCV13 effectiveness was calculated by taking into account both direct 
effectiveness from PCV7 and the serotype producing systemic disease in Switzerland
26
. 
Vaccine effectiveness is defined as the proportion of vaccinated population that exhibits 
immunity to vaccine covered serotype of pneumococcal bacteria. 
Effectiveness against covered types indicates the effectiveness of the vaccine against the 
serotypes included in the vaccine. For the heptavalent vaccine, direct efficacy among 
children below one year of age was estimated at 72.3%, 6.0%, 6.0%, and 7.0% for IPD, 
inpatient pneumonia, outpatient pneumonia and all-cause otitis media, respectively
28, 29
. 
Effectiveness against IPD for covered serotypes was assumed equal for PCV7 and 
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PCV13
23, 28
. Non-IPD effectiveness against covered types was expected to be the same 
for PCV7 and PCV13. Hence, the effect for non-IPD was calculated based on direct 
PCV7 effect and the increase in the additional serotype coverage provided by PCV13 as 
observed in the Swiss population ((PCV13 effectiveness = effectiveness of PCV7 * (1 + 
(serotype coverage of PCV13 / serotype coverage of PCV7)). Correspondingly, direct 
effects of PCV13 was calculated for children below 2 years of age (Table 4).  
It was assumed that the vaccine effectiveness (cases avoided) among children <12 
months was reduced by 1/3 to reflect children <2 months that were not vaccinated and 
children 2-<4 months who may not mount an immune response. Direct effect was 
assumed to decline by 3% annually in the first three years of life (waining of 9% in 
total)
30, 31
. Hence 91% of the original vaccine efficacy was applied for children of the age 
group 3-5 years
30
.  
Vaccine indirect effect 
The indirect or herd effect provides indirect protection to unvaccinated individuals given 
that vaccinated individuals are less likely to carry vaccine-type pneumococci
32, 33
. The 
impact of acceleration of indirect effects is hard to determine, however we presumed herd 
effects of PCV7 for IPD and non-IPD (complex otitis media Sand hospitalised 
pneumonia) derived from published literature
34
. PCV13 indirect effectiveness against 
covered types for non-IPD was assessed based on the indirect effectiveness of PCV7 and 
its proportional serotype coverage (Appendix 1, Table 3). In order to use a conservative 
approach, we divided the additional age-specific serotype adjustment by two.  
The vaccine was assumed to have a direct effect in children below the age of five
28, 29
, but 
decreased rates of disease incidence in individuals aged five years and above were 
  10 
 
assumed to be due to indirect vaccine effects (Table 4, Appendix 1)
10
. The expected 
proportion of reduced disease cases in IPD and non-IPD stands for the indirect 
effectiveness of non-vaccinated individuals . After seven years of initial vaccination, the 
indirect effects reached a cumulative steady state of 100%.  
2.6. Unit costs 
Direct medical costs included vaccine related costs, physician time, medication, 
diagnostic tests consumed and hospitalization costs. Unit costs for vaccine 
administration, laboratory and diagnostic interventions derived from the official Swiss 
tariff book
35
. Hospital case-based flat rates and day rates were based on Swiss Diagnosis 
Related Groups (DRGs)
36
. Drug and vaccine costs were based on official Swiss 
pharmacy prices
37
. 
38
 Health states with no disease were assumed to have no costs, 
besides the cost of the vaccine. Costs and quantity of diagnostics and therapeutic 
interventions were assessed on this basis for all disease outcomes assessed (Appendix 2). 
We did not include indirect costs to society as loss of income due to death or severe 
sequelae.  
2.7. Medical resource use 
Resource utilisation quantities for pneumococcal diseases were obtained from expert 
panel consultation and systematic literature research.  
One meningitis episode was assumed to require radiology, computer tomography (CT) 
and magnet resonance imaging (MRI) of the cranum, hearing tests, lumbal puncture and 
culture. During a bacteremia episode, radiology, computer tomography (CT) and magnet 
resonance imaging (MRI) of the thorax, lumbal puncture and culture was presumed to be 
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needed. Diagnostic interventions for pneumonia and otitis media  episode were CT, 
radiography and MRI of the thorax, depending on the complexity of the disease course. It 
was assumed that 20% of complex otitis media cases would require a ventilator tube 
replacement
39
. 
Length of hospital stay was based on data provided by the Swiss Federal Statistic Office 
(adults≥18 years) and expert opinion (children<18years)40. Admission rates and average 
hospital stay are presented in Appendix 3. In all cases, blood tests and antipyretic / 
analgesic drugs were prescribed, hence those costs were not included in the model. The 
model took into account future medical costs of €820 (deafness) and €4’100 (disability) 
per year for children with sequelae from meningitis
15
.  
2.8. Utilities 
Preference-based measures of health related quality of life were available from the 
published literature
15, 41-45
. Utilities are measured on a 0-1 scale where 1 corresponds to 
perfect health. Baseline utility for a healthy individual was 0.9
46
. Per episode utility 
reduction for meningitis (0.0232)
41
, bacteremia (0.0079)
41
, simple (0.004)
45
 and complex 
pneumonia (0.006)
45
 as well as  otitis media (0.005)
44
 were used in the model. Hearing 
loss and disability were assumed to reduce a patient’s lifetime utility by a factor of 0.8 
and 0.6, respectively
42, 43
. Utility values were supposed to be independent of age.  
Total QALYs were determined by multiplying discounted average life expectancy with 
the health utility index of an individual in a certain health state. QALYs lost due to 
disease sequelae were subtracted from the QALYs of the entire population to obtain the 
total QALYs.  
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2.9. Sensitivity analysis 
Deterministic sensitivity analyses (DSA) were performed to test the impact of parameter 
uncertainties on the number of pneumococcal cases avoided and according cost 
consequences. The following variables were included in the sensitivity analyses (DSA 
cases): vaccination coverage of PCV7, vaccination coverage of PCV13, incidence simple  
otitis media, direct effectiveness of PCV13 versus simple otitis media, waning of direct 
effectiveness, incidence of IPD, IPD direct effectiveness of PCV13, incidence of complex 
otitis media, indirect effectiveness of simple otitis media of PCV13, direct effectiveness 
of PCV13 versus complex otitis media. DSA in regard to costs were performed with the 
variables as follows: incidence of IPD, indirect IPD effectiveness of PCV13, medical 
costs of bacteremia, costs of 1 vaccine dose, annual medical cost of disability, proportion 
of IPD cases that are meningitis, medical costs of simple otitis media, incidence of simple 
otitis media, medical costs of meningitis and incidence of complex otitis media. All 
variables were varied within ±20 %.  
III.  Results 
3.1. Base-case result (PCV13 vs PCV7) 
The base-case measured the impact of PCV13 as the reduction in the burden of disease 
and associated costs. With 83% vaccination coverage, a total of 660'563 children would 
be vaccinated during a ten-year period (yearly average: 66'056).  
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Epidemiologic result 
The direct effect of the vaccine accounts for a considerable reduction in disease cases in 
the PCV13 vaccine programme. The proportion of IPD and non-IPD cases avoided in 
non-vaccinated individuals (age 5 years and above) can be attributed to herd immunity 
(Table 4).  
The model assumed that, in addition to the benefit of PCV7, PCV13 would reduce the 
number of pneumococcal meningitis and bacteraemia (IPD) by further 1’808  cases. 
Furthermore, it was estimated that 4’654 and  904 hospitalized and non-hospitalized 
pneumonia cases could be averted in the entire Swiss population, respectively. The 
incremental number of all-cause otitis media cases for the comparator strategy relative to 
the baseline strategy includes the cumulative number of the young population below five 
years of age over the entire modelling period. With the implementation of PCV13, it is 
estimated that additional 215  IPD related fatalities could be avoided (Table 5).  
Costs  
The cost estimates per disease episode differed considerably. In fact, highest costs per 
episode were found for complex diseases like meningitis, bacteriemia, hospitalised 
pneumonia and complex otitis media with €10’713, €4’887, €4’286 and €1’793, 
respectively. Less complex diseases as e.g. Simple otitis media or non-hospitalised 
pneumonia resulted in about €140 and €295 per episode, respectively (Appendix 4).  
The vaccination programme with PCV13 would require an additional investment of about 
€26.2 Mio assuming a constant vaccine coverage of 83%. On the other hand, PCV13 
resulted in costs savings of €18.3 Mio, €34.0  Mio and € 25.6  Mio attributed to IPD, 
pneumonia and all-cause otitis media, respectively. Accordingly, direct medical costs of 
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about -€ 96.9 Mio could be saved by PCV13, leading to total cost savings of –€77.1  Mio 
in Switzerland (Table 5).  
Cost-effectiveness  
Base-case 
Across the entire Swiss population, the PCV13 vaccination programme saved 23’242  
life-years and gained 18’172  QALYs over a ten-year period. This translates into a cost-
saving situation of –€77  per child vaccinated(Table 5). If no herd protection would be 
considered, the cost-effectiveness ratio would increase to EUR 16'342 per QALY gained 
with costs of EUR 10 per child vaccinated (LYG=0). Catch-up programme 
In the catch-up strategy, 42'360 children would receive catch-up vaccination (up to 59 
months of age). The model predicts that the implementation of a catch-up programme for 
children aged 12-59 months in Switzerland would lead to direct protection combined with 
accelerated indirect impact resulting in 196 IPD and 3'592 non-IPD cases avoided and 
275 averted deaths. In fact, the catch-up programme gained  1'608 QALYs and 2'182 life 
years. The additional vaccine course would cost additional €+4.0 Mio, whereas averted 
disease cases and disease related fatalities yielded in reduced medical costs of -€9.4 Mio. 
Accordingly, the cost-effectiveness ratio resulted in a cost-saving situation (Table 5). By 
considering only children below the age of 2 years in the catch-up programme, the 
situation would translate into cost-savings of €1'189 per child vaccinated.   
3.2. Sensitivity analyses  
By the help of sensitivity analyses, the robustness of the model base-case could be 
assessed. For the deterministic sensitivity analyses, cost and effectiveness were varied to 
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the extremes of ±20%. The strongest impact on the number of avoided pneumococcal 
cases found in the base-case was obtained by varying the vaccination coverage and the 
incidence of simple  all-cause otitis media. On the other hand, the base-case result 
regarding the costs was mainly influenced by the medical costs of hospitalised 
pneumonia, the incidence of hospitalised pneumonia as well as PCV7 indirect effect of 
averting hospitalised pneumonia (Figure 2).  
IV.  Discussion and conclusion 
In our analysis, we assessed the prospective cost-effectiveness of a vaccination 
programme with PCV13 compared to the current available PCV7. The model included 
the impact of direct and indirect vaccine effects among the entire Swiss population. 
Although the introduction of PCV13 would increase the expenses for the pneumococcal 
vaccine program itself when compared to PCV7, the reduced medical costs due to 
avoided cases would overcompensate these costs over a ten year period. PCV13 
vaccination would result in a cost-saving situation. The additional option of a catch-up 
vaccine programme indicated a favourable cost-effectiveness ratio when compared to the 
normal PCV13 vaccination schedule. Neither variation of cost- nor effectiveness input 
parameters did influence the model base-case results. 
Rozenbaum and colleagues have recently presented a health economic evaluation with an 
unfavourable cost-effectiveness ratio for PCV7 in Dutch infants when net indirect effects 
(herd protection minus serotype replacement) were omitted (both for the 2+1 and 3+1 
immunisation schedule)
47
. The authors concluded that PCV7 does not provide enough 
protection with the serotypes included and hence does not lead to a health economic 
favourable result. However, by considering PCV13 vaccination with a three dose 
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schedule (2+1), the achieved cost-effectiveness ratio would be much favourable 
(€33’481/QALY compared to no vaccination). The better net health benefits of PCV13 
can be mainly attributed to better herd immunity and reduced serotype replacement.  
The major limiting factor was the data source. Although we tried to identify the most 
relevant and appropriate data, our model represents a simplification of the real-life 
disease outcome. For example, we did not take into account infections like endocarditis, 
arthritis, osteomyelitis, sinusitis or peritonitis, which might be linked to pneumococcal 
infections, especially among the adult population. Furthermore, most input parameters in 
regard to disease transmission came from various sources outside Switzerland, due to the 
lack of Swiss numbers. In addition, direct and indirect effects of PCV13 are yet not to be 
studied in the Swiss population. Hence, the data were calculated based on effects 
observed with PCV7 and the increase in serotype coverage of PCV13 compared to the 
seven-valent vaccine. This approach was also used in other studies
48, 49
. Consequently, 
extensive sensitivity analyses have been performed to assess the robustness of the input 
parameters on the model’s base-case result. We recognise that altered variable 
assumptions might have resulted in altered model results, but did not affect the 
conclusion of the analysis.  
It may be argued that the cost-effectiveness ratio is indirectly driven by the applied 
indirect effects of the vaccine
32
. However, it remains unclear, if the herd immunity of 
PCV13 which was based on information derived from PCV7, is applicable to the 
serotypes covered. In our base-case analysis, we have taken into account herd protection 
of the unvaccinated individuals resulting in a reduction of the mortality rate of 2’886. In a 
sub-analysis, we have run the model omitting the indirect effect of the vaccination. 
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Nevertheless, the outcome of this analysis was still cost-saving. This underlines the work 
of Isaacman et al who investigated in a review whether indirect effects impacts the cost-
effectiveness results
14
. The review come to the conclusion that indirect effects impact the 
cost-effectiveness considerable, and future models should include herd immunity when 
assessing the health economic impact of pneumococcal vaccines.  
Due to the growing number of new vaccines, health economic models on immunisation 
programmes are more and more important to inform decision makers on health policies
47
. 
Several studies have shown that PCV7 can be assumed cost-effective or even cost-saving, 
both in the Swiss
15
 and non-Swiss setting
27, 30, 50-52
. It can be expected, that PCV13 may 
enhance the overall direct effect of the vaccination and offers positive herd protection in 
the non-vaccinated population.  
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Figure legend 
Figure 1. Decision analytic model structure 
Figures 2 Deterministic Sensitivity Analyses (variables varied by ±20%) 
a) Effectiveness  
b) Costs (Euro) 
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Table 1. Current annual incidence of IPD, pneumonia and all cause otitis media  per 
age group (cases per 100’000 person-years, 2007/08) 
 
 IPD* IPD that 
are 
meningiti
s  
IPD with 
pneumon
ia 
CAP all* CAP 
inpatient 
CAP 
outpatien
t 
 all-cause 
otitis 
media** 
all 
all-cause 
otitis 
media 
complex 
all-cause 
otitis 
media 
simple 
year 2008 2008 2008 2007 2007 2007 2007 2007 2007 
age groups        
<12 
months 
32 33% 21% 280 42 238 15379 1538 13841 
12-23 
months 
8 33% 33% 408 61 347 21539 2154 19385 
24-35 
months 
12 0% 78% 328 49 278 14909 1491 13418 
36-47 
months 
11 0% 63% 273 41 232 14802 1480 13322 
48-59 
months 
13 0% 30% 231 35 196 14726 1473 13254 
5-17 years 3 19% 66% 70 11 60 - - - 
18-34 
years 
3 5% 59% 42 6 36 - - - 
35-49 
years 
8 10% 65% 71 11 60 - - - 
50-64 
years 
14. 7% 65% 167 25 142 - - - 
65+ years 44 5% 70% 810 121 688 - - - 
; CAP, community acquired pneumonia; IPD, invasive pneumococcal disease. 
*it is assumed that 15% of CAP cases are hospitalized 
**it is assumed that 10% of AOM are moderate to severe cases 
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Table 2. Fatality rates 
 IPD all Meningitis Sepsis Pneumonia all CAP (2007) 
Unit (%)  (%)  (%) (%) (%) 
Notes Proportion of 
deaths per cases of 
IPD 
Proportion of 
deaths with 
meningitis per IPD 
cases with 
meningitis 
Proportion of 
deaths with sepsis 
per IPD cases with 
sepsis 
Proportion of 
deaths with 
pneumonia per IPD 
cases with 
pneumonia* 
Death of CAP was 
assumed to be all 
inpatient cases 
age groups      
<12 to 59 
months 
0 0 0 0 0 
5-17 years 0 0 0 0 0.17 
18-34 years 0 0 0 0 0.76 
35-49 years 5.3 0 10.0 4.0 2.71 
50-64 years 8.3 28.6 13.4 6.0 11.43 
65+ years 15.0 26.9 24.6 13.2 84.93 
CAP, community acquired pneumonia; IPD, invasive pneumococcal disease. 
*Hospitalization status of patients with pneumonia is not reported and therefore not known  
NB: Multimanifestations are possible: one case may be counted to death with meningitis, with sepsis and with pneumonia 
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Table 3. 7-valent and 13-valent vaccine serotype coverage against all diseases (2006 / 
2008) 
Age group PCV7*(2006)  Ref PCV13**(2008)  Ref 
<12 months 60.4% 25 85.7% 26 
12-23 months 60.4% 100.0% 
24-35 months 53.6% 100.0% 
36-47 months 53.6% 100.0% 
48-59 months 53.6% 100.0% 
5-17 years 34.4% 89.3% 
18-34 years 42.8% 74.1% 
35-49 years 42.8% 69.1% 
50-64 years 42.8% 70.7% 
65+ years 38.2% 72.8% 
*Serotypes: 4; 6B; 9V; 14; 18C; 19F; 23F 
**Serotypes: 1; 3; 4; 5; 6A; 6B; 7F; 9V; 14; 18C; 19A; 19F; 23F 
NB: Cross-protection was not considered 
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Table 4. Direct and indirect effect due to PCV13 
Direct effect25, 26, 29* 
 IPD Pneumonia Otitis Media 
 
age groups 
Hospitalized Non-
hospitalized 
Complex Simple 
<12 months** 41% 9% 9% 10% 10% 
12-23 months 75% 16% 16% 19% 19% 
Catch-up vaccination 
24- months 73% 17% 17% 10% 10% 
36-47 months 70 17% 17% 5% 5% 
48-59 months 59 17% 17% 5% 5% 
Indirect effect25, 26, 34 (Reduction in disease not attributable to direct effect)*** 
 IPD Hospitalized pneumonia Complex otitis media 
<12 months**  48% 33% 22% 
12-23 months 56% 42% 27% 
24-35 months 43% 37% 0% 
Catch-up: 29% 
36-47 months 43% 37% 0% 
Catch-up: 29% 
48-59 months 41% 54% 0% 
Catch-up: 29% 
5-17 yrs 37% 57%  
18-34 yrs 32% 25% 
35-49 yrs 30% 23% 
50-64 yrs 27% 22% 
65+ yrs 14% 24% 
IPD, invasive pneumococcal disease. 
* non-IPD direct effect PCV13 = indirect effect PCV7 * (1 + ((serotype coverage of PCV13 / serotype coverage of PCV7)). 
** It was assumed that the vaccine efficacy among children <12 months is reduced by 1/3 to reflect children <2 months that are not 
vaccinated and children 2-<4 months who may not mount an immune response. 
  24 
 
***non-IPD indirect effect PCV13 = indirect effect PCV7 * (1 + ((serotype coverage of PCV13 / serotype coverage of PCV7)/2)). 
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Table 5. Base case and catch-up: cost-effectiveness results 
 
 PCV13 versus PCV7 Catch-up program 
Difference in direct costs (EUR) -77.1 Mio -9.4 Mio 
Difference in vaccination costs (EUR) +26.2 Mio  +4.0 Mio 
Life years gained 23’242 2'182 
QALYs gained 18’172 1'608 
Cases avoided 
IPD 1’808 196 
Hospitalized pneumonia 4’654 535 
Non-hospitalized pneumonia 904 39 
Complex all-cause otitis media 11'590 1'513 
Simple all-cause otitis media 62'546 1'505 
Death avoided 
IPD 215 25 
Hospitalized pneumonia 2’125 250 
Cost-effectiveness results 
Cost (EUR) per LYG Cost-saving Cost-saving 
Cost (EUR) per QALY Cost-saving Cost-saving 
Cost (EUR) per vaccinated child -77  -222 
IPD,  invasive pneumococcal disease; QALY, quality adjusted life years, LYG, life year gained 
NB: no deaths in 0-17 years old individuals 
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